Loading...

CSL Limited

CSL.AXASX
Healthcare
Biotechnology
A$226.00
A$5.26(2.38%)

CSL Limited (CSL.AX) Stock Competitors & Peer Comparison

See (CSL.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CSL.AXA$226.00+2.38%109.4B23.64A$9.56+1.88%
TLX.AXA$18.10+6.97%6.1B129.29A$0.14N/A
MSB.AXA$2.37+2.16%3B-12.47-A$0.19N/A
NEU.AXA$17.33+2.36%2.1B15.90A$1.09N/A
CU6.AXA$3.54+2.61%1.3B-22.12-A$0.16N/A
PYC.AXA$1.32+3.53%769.9M-12.00-A$0.11N/A
OPT.AXA$0.60+0.00%738.8M-1.40-A$0.43N/A
CUV.AXA$11.99+2.74%601M15.57A$0.77+0.42%
IMM.AXA$0.25+0.00%359.6M-8.17-A$0.03N/A
OCC.AXA$1.20+0.84%292.5M-59.75-A$0.02N/A
Showing 1 to 10 of 57 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CSL.AX vs TLX.AX Comparison August 2025

CSL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSL.AX stands at 109.4B. In comparison, TLX.AX has a market cap of 6.1B. Regarding current trading prices, CSL.AX is priced at A$226.00, while TLX.AX trades at A$18.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSL.AX currently has a P/E ratio of 23.64, whereas TLX.AX's P/E ratio is 129.29. In terms of profitability, CSL.AX's ROE is +0.17%, compared to TLX.AX's ROE of +0.10%. Regarding short-term risk, CSL.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CSL.AX.Check TLX.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;